Outcomes for COPD pharmacological trials: from lung function to biomarkers
M Cazzola, W MacNee, FJ Martinez… - European …, 2008 - publications.ersnet.org
The American Thoracic Society/European Respiratory Society jointly created a Task Force
on “Outcomes for COPD pharmacological trials: from lung function to biomarkers” to inform …
on “Outcomes for COPD pharmacological trials: from lung function to biomarkers” to inform …
Chronic obstructive pulmonary disease and related phenotypes: polygenic risk scores in population-based and case-control cohorts
Background Genetic factors influence chronic obstructive pulmonary disease (COPD) risk,
but the individual variants that have been identified have small effects. We hypothesised that …
but the individual variants that have been identified have small effects. We hypothesised that …
Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID …
NG McElvaney, J Burdon, M Holmes… - The Lancet …, 2017 - thelancet.com
Background Purified α1 proteinase inhibitor (A1PI) slowed emphysema progression in
patients with severe α1 antitrypsin deficiency in a randomised controlled trial (RAPID-RCT) …
patients with severe α1 antitrypsin deficiency in a randomised controlled trial (RAPID-RCT) …
Machine learning and prediction of all-cause mortality in COPD
Background COPD is a leading cause of mortality. Research Question We hypothesized that
applying machine learning to clinical and quantitative CT imaging features would improve …
applying machine learning to clinical and quantitative CT imaging features would improve …
CT-quantified emphysema in male heavy smokers: association with lung function decline
FAAM Hoesein, B de Hoop, P Zanen, H Gietema… - Thorax, 2011 - thorax.bmj.com
Background Emphysema and small airway disease both contribute to chronic obstructive
pulmonary disease (COPD), a disease characterised by accelerated decline in lung …
pulmonary disease (COPD), a disease characterised by accelerated decline in lung …
Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed …
RA Stockley, DG Parr, E Piitulainen, J Stolk… - Respiratory …, 2010 - Springer
Background Two randomised, double-blind, placebo-controlled trials have investigated the
efficacy of IV alpha-1 antitrypsin (AAT) augmentation therapy on emphysema progression …
efficacy of IV alpha-1 antitrypsin (AAT) augmentation therapy on emphysema progression …
Emphysema progression at CT by deep learning predicts functional impairment and mortality: results from the COPDGene study
Background Visual assessment remains the standard for evaluating emphysema at CT;
however, it is time consuming, is subjective, requires training, and is affected by variability …
however, it is time consuming, is subjective, requires training, and is affected by variability …
Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review
RG Edgar, M Patel, S Bayliss, D Crossley… - … journal of chronic …, 2017 - Taylor & Francis
Background Alpha-1 antitrypsin deficiency (AATD) is a rare genetic condition predisposing
individuals to chronic obstructive pulmonary disease (COPD). The treatment is generally …
individuals to chronic obstructive pulmonary disease (COPD). The treatment is generally …
[HTML][HTML] Brd4-p300 inhibition downregulates Nox4 and accelerates lung fibrosis resolution in aged mice
YY Sanders, X Lyv, QJ Zhou, Z Xiang, D Stanford… - JCI insight, 2020 - ncbi.nlm.nih.gov
Tissue regeneration capacity declines with aging in association with heightened oxidative
stress. Expression of the oxidant-generating enzyme, NADPH oxidase 4 (Nox4), is elevated …
stress. Expression of the oxidant-generating enzyme, NADPH oxidase 4 (Nox4), is elevated …
[引用][C] European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency
M Miravitlles, A Dirksen, I Ferrarotti… - European …, 2017 - Eur Respiratory Soc